Hundreds of scientists, regulators, and investors from China and the US gathered in Gaithersburg, Maryland, on June 11, 2016 to attend the 21st Annual Conference of the Chinese Biopharmaceutical Association (known as CBA), a Maryland-based non-profit organization striving to serve as “the bridge of US-China biopharmaceuticals.”
From the advances in immune-oncology and precision medicine, to regulatory challenges in global drug development, the one-day conference covered a wide range of topics.
Here are a few highlights pertinent to drug development in China.